688139.SHG Qingdao Haier Biomedical Co Ltd
- Market cap
- CNY 10.6B
- P/E
- 38.6x
- P/B
- 2.19x
- ROE
- 6.5%
- Dividend yield
- 1.39%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688139.SHG undervalued?
Graham number688139.SHG trades 93.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Qingdao Haier Biomedical Co Ltd fundamental analysis
No fundamental analysis for Qingdao Haier Biomedical Co Ltd yet.
Qingdao Haier Biomedical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Qingdao Haier Biomedical Co Ltd
Qingdao Haier Biomedical Co.,Ltd engages in the research and development, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples in China and internationally. The company offers ULT freezers, pharmacy refrigerators, freezers, automatic storage solutions, cryogenics, active temperature controlled RKN containers, and RTMD products; and CO2 incubation, standard incubators, biological safety cabinets, clean benches and laminar, and steriliza…
Full company profileQingdao Haier Biomedical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Qingdao Haier Biomedical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 482M | 621M | 842M | 1.01B | 1.40B | 2.13B | 2.86B | 2.28B | 2.28B | 2.33B | 2.62B |
| Gross Profit | 255M | 329M | 427M | 543M | 708M | 1.07B | 1.38B | 1.11B | 1.10B | 1.09B | 1.24B |
| Operating Income | 128M | 62.5M | 109M | 209M | 322M | 464M | 595M | 335M | 343M | 234M | 286M |
| EBITDA | - | 97.5M | 183M | 223M | 447M | 1.01B | 742M | 541M | 526M | 394M | 321M |
| Net Income | 123M | 60.4M | 114M | 182M | 381M | 845M | 601M | 406M | 367M | 251M | 293M |
| EPS | - | 0.25 | 0.48 | 0.57 | 1.20 | 2.67 | 1.89 | 1.28 | 1.15 | 0.79 | 0.93 |
| Balance Sheet | |||||||||||
| Total Assets | 949M | 1.19B | 2.23B | 3.04B | 3.94B | 4.90B | 5.49B | 5.53B | 5.79B | 5.79B | 5.95B |
| Total Liabilities | 226M | 576M | 1.11B | 581M | 1.16B | 1.26B | 1.34B | 1.09B | 1.17B | 1.17B | 1.17B |
| Shareholders' Equity | 723M | 615M | 1.11B | 2.45B | 2.78B | 3.62B | 4.02B | 4.23B | 4.37B | 4.38B | 4.50B |
| Cash & Short-term Investments | 135M | 145M | 372M | 1.41B | 1.85B | 774M | 952M | 1.27B | 901M | 844M | 996M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 221M | 148M | 149M | 280M | 697M | 632M | 632M | 249M | 292M | 268M | - |
| Capital Expenditure | 14.5M | 27.0M | 69.3M | 168M | 89.0M | 205M | 294M | 177M | 127M | 119M | 69.2M |
| Free Cash Flow | - | 121M | 79.7M | 112M | 608M | 387M | 338M | 72.1M | 165M | 149M | 179M |
| Ratios | |||||||||||
| ROE | 17.0% | 9.8% | 10.3% | 7.4% | 13.7% | 23.3% | 14.9% | 9.6% | 8.4% | 5.7% | 6.5% |
| ROA | 13.0% | 5.1% | 5.1% | 6.0% | 9.7% | 17.2% | 10.9% | 7.3% | 6.3% | 4.3% | 4.9% |
| Net Profit Margin | 25.6% | 9.7% | 13.5% | 18.0% | 27.2% | 39.8% | 21.0% | 17.8% | 16.1% | 10.8% | 11.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Qingdao Haier Biomedical Co Ltd dividends
- Dividend yield
- 1.39%
- Forward dividend
- 0.33 CNY
- Payout ratio
- 58.8%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 147M | 0.46 | 58.8% |
| 2024 | CNY 163M | 0.51 | 44.5% |
| 2023 | CNY 143M | 0.45 | 35.2% |
| 2022 | CNY 162M | 0.51 | 27.0% |
| 2021 | CNY 121M | 0.38 | 14.3% |
| 2020 | CNY 57.1M | 0.18 | 15.0% |
| 2019 | CNY 25.7M | 0.08 | 14.1% |
| 2018 | CNY 245M | 1.03 | 215.0% |
| 2017 | CNY 245M | 1.03 | 405.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Qingdao Haier Biomedical Co Ltd
- Insiders 42.31%
- Institutions 19.44%
- Public & others 38.25%
- Shares outstanding 316M
- Free float 148M
Qingdao Haier Biomedical Co Ltd company profile
- Company name
- Qingdao Haier Biomedical Co Ltd
- Ticker
- 688139.SHG
- ISIN
- CNE100003P25
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,945
- Fiscal year end
- December
- Address
- No. 280 Feng Yuan Road, Qingdao, China, 266114
- Phone
- 86 532 8893 5566
- Website
- haierbiomedical.com
About Qingdao Haier Biomedical Co Ltd
Qingdao Haier Biomedical Co.,Ltd engages in the research and development, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples in China and internationally. The company offers ULT freezers, pharmacy refrigerators, freezers, automatic storage solutions, cryogenics, active temperature controlled RKN containers, and RTMD products; and CO2 incubation, standard incubators, biological safety cabinets, clean benches and laminar, and sterilization products. It also provides floor standing, benchtop refrigerated, and benchtop centrifuges; intelligent pharmacy automation and RFID pharmacy products; blood bank refrigerators, blood component management products, blood plasma freezers, and transport coolers; and vaccine storage, cold/freezer room, medical waste disposal equipment, and other products. In addition, the company offers freezer and controlled rate freezers; microwave digestion system; UV visible spectrophotometer and total organic carbon analyzer products; and consumables. Further, it provides after-sales services; and U-biobank, U-vaccine, U-reagent, U-blood, and U-laboratory network solutions. The company serves hospitals, bio and pharmaceutical enterprises, universities and colleges, scientific research institutions, centers for disease control, primary public health institutions and blood stations. Qingdao Haier Biomedical Co.,Ltd was founded in 2005 and is based in Qingdao, China.
Qingdao Haier Biomedical Co Ltd management
6- Dr. Zhanjie LiuGM & Employee Representative Director · born 1970
- Ms. Ruijuan MoChief Financial Officer · born 1981
- Ms. Yanli HuangBoard Secretary · born 1987
- Nai Juan MuAccounting Supervisor
- Mr. Ji Yuan LiuExecutive Officer · born 1984
- Mr. Pei Kun TengPlanning Director and Head of the Tianjin R&D Center · born 1986